819 results on '"Siveke, Jens T."'
Search Results
2. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
3. Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment
4. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation
5. P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy
6. Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009–2021
7. SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axis
8. Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy
9. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma
10. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer
11. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization
12. Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma
13. MCL1 as putative target in pancreatoblastoma
14. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer
15. Prognostic Implications of68Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors
16. 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
17. Radiation Dose Aspects of Hepatic Artery Infusion Chemotherapy in Uveal Melanoma Patients with Liver Metastases
18. Das Pankreaskarzinom: Klinische Projekte der onkologischen Studiengruppen in Deutschland (ACO, AIO und ARO)
19. [68Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas
20. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
21. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression
22. 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.
23. Prognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.
24. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer.
25. Diagnostic Accuracy of68Ga-FAPI Versus18F-FDG PET in Patients with Various Malignancies
26. Multimodale Therapie ampullärer Karzinome
27. Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion
28. A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis
29. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
30. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1
31. [68Ga]Ga-FAPI versus 2-[18F]FDG PET/CT in patients with autoimmune thyroiditis: a case control study.
32. Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization
33. Fibroblast Activation Protein α–Directed Imaging and Therapy of Solitary Fibrous Tumor
34. P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy
35. 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the68Ga-FAPI PET Observational Trial
36. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
37. Cellular model system to dissect the isoform-selectivity of Akt inhibitors
38. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
39. Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma
40. Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression
41. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma
42. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
43. The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma
44. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial
45. Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription
46. Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence
47. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
48. Supplementary Table S3 from Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma
49. Supplementary Methods from Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma
50. Supplementary Figure S1 from Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.